| Variables |
Males (N=91, 24%) |
Females (N= 289, 76%) |
Total patients (N= 380, 100%) |
Total patients (N= 380, 100%) |
Level of significance |
| CD4+ cell count /µL |
At baseline |
At time of ADR |
At baseline |
At time of ADR |
At baseline |
At time of ADR |
Χ2 =26.764, P = 0.00 |
| 20-100 |
34 (8.9) |
0 |
147 (38.7) |
14 (3.7) |
181(47.6) |
14 (3.6) |
| 101- 200 |
56 (14.7) |
59 (15.5) |
100 (26.3) |
36 (9.5) |
156 (41.1) |
95 (25.0) |
| 201-350 |
1(0.3) |
12 (3.2) |
42 (11.0) |
201(52.9) |
43 (11.3) |
213 (56.1) |
| ≥ 351 |
0 |
20 (5.3) |
0 |
38 (10.0) |
0 |
58 (15.3) |
| Median CD4+ |
124 (20-249) |
124 (20-480) |
110 (20-249) |
256 (78-506) |
|
|
t = -8.136, P = 0.01 |
| Virologic status |
At baseline |
At time of ADR |
At baseline |
At time of ADR |
At baseline |
At time of ADR |
|
| Patients with Detectable plasma viral load |
91(24.0) |
47 (12.4) |
289 (76.0) |
200 (52.6) |
380 (100.0) |
247 (65.0) |
Χ2 =26.764, P = 0.00 |
| Patients with undetectable plasma viral load |
0 |
44 (11.5) |
0 |
89 (23.5) |
0 |
133 (35.0) |
|
